NCT07398040

Brief Summary

The goal of this clinical trial is to evaluate the effectiveness of an anti-inflammatory dietary intervention on physical health, mental health, and cognitive functioning in individuals with clinically diagnosed anxiety and/or depression, and to assess the agreement between artificial intelligence-based analysis of verbal and non-verbal language patterns and standard psychometric assessment tools. The study will include adult participants (≥18 years) with a clinical diagnosis of anxiety and/or depressive disorder, irrespective of sex or gender. The main questions it aims to answer are: Does a 4-month anti-inflammatory dietary intervention improve mental health outcomes (anxiety and depressive symptoms) compared to a control condition in individuals with anxiety and/or depression? Does the intervention lead to improvements in physical health and cognitive functioning relative to the control group? Are verbal and non-verbal language patterns analyzed using artificial intelligence coherent with the results obtained from validated anxiety and depression questionnaires at baseline? Do changes in AI-derived language markers parallel changes in clinical and self-reported outcomes following the dietary intervention? Primary outcomes / hypotheses: Does the anti-inflammatory dietary intervention produce greater reductions in anxiety and depressive symptom severity compared to the control group after 4 months? Does the intervention result in significant improvements in physical health and cognitive performance compared to the control group? Researchers will compare the anti-inflammatory diet intervention group with the control group (usual diet or standard dietary advice) to determine whether the intervention leads to superior improvements in mental, physical, and cognitive health outcomes. Participants will: Complete baseline assessments including validated questionnaires on anxiety, depression, physical health, cognitive functioning, and quality of life. Undergo structured interviews at baseline during which verbal and non-verbal language data will be recorded and analyzed using artificial intelligence-based models. Be allocated to either the anti-inflammatory dietary intervention group or the control group. Follow their assigned dietary condition for 4 months. Complete post-intervention assessments identical to baseline, including psychometric questionnaires and cognitive and physical health evaluations.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
5mo left

Started Jan 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress49%
Jan 2026Sep 2026

First Submitted

Initial submission to the registry

January 13, 2026

Completed
3 days until next milestone

Study Start

First participant enrolled

January 16, 2026

Completed
24 days until next milestone

First Posted

Study publicly available on registry

February 9, 2026

Completed
19 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2026

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2026

Expected
Last Updated

February 9, 2026

Status Verified

February 1, 2026

Enrollment Period

1 month

First QC Date

January 13, 2026

Last Update Submit

February 2, 2026

Conditions

Keywords

DepressionAnxietyAnti-inflammatory dietArtificial Intelligence

Outcome Measures

Primary Outcomes (5)

  • Anxiety level (Depression, Anxiety, Stress Scale; DASS-42)

    From enrollment to the end of treatment at 16 weeks

  • Depression level (Depression, Anxiety, Stress Scale; DASS-42)

    From enrollment to the end of treatment at 16 weeks

  • SF-36

    From enrollment to the end of treatment at 16 weeks

  • GLUCEMIC PROFILE

    From enrollment to the end of treatment at 16 weeks

  • INFLAMMATORY PROFILE

    From enrollment to the end of treatment at 16 weeks

Secondary Outcomes (9)

  • Gastrointestinal symptoms (Gastrointestinal Symptom Rating Scale)

    From enrollment to the end of treatment at 16 weeks

  • Physical activity (International Physical Activity Questionnaire)

    From enrollment to the end of treatment at 16 weeks

  • Sleep quality (Pittsburg Sleep Quality Index)

    From enrollment to the end of treatment at 16 weeks

  • Food Frequency Questionnaire

    From enrollment to the end of treatment at 16 weeks

  • Adherence to Mediterranean diet (MEDAS Scale)

    From enrollment to the end of treatment at 16 weeks

  • +4 more secondary outcomes

Study Arms (2)

Anti-inflammatory diet

EXPERIMENTAL
Other: Anti-inflammatory diet

Control

ACTIVE COMPARATOR
Other: Control

Interventions

We will use an anti-inflammatory diet to assess its impact on physical, mental and cognitive health

Anti-inflammatory diet
ControlOTHER

No intervention

Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Presence of mild, moderate, or severe symptoms of anxiety, depression, or stress, as measured by the DASS-42 questionnaire.
  • Absence of medical contraindications to following a personalized diet.
  • Absence of cognitive impairment.
  • Proficiency in the Spanish language (ability to speak and understand fluently).
  • Availability over a 4-month period to attend scheduled assessments and intervention sessions.
  • Low or moderate adherence to the Mediterranean diet, as assessed by the Mediterranean Diet Adherence Questionnaire (score ≤ 9 out of 14).
  • Residence in the city of Zaragoza for the entire duration of the study.
  • Signed informed consent after receiving detailed information about the study.

You may not qualify if:

  • Presence of organic pathologies that prevent adherence to the dietary intervention or that significantly interfere with the conduct of the study.
  • Inability to attend the scheduled in-person sessions.
  • Diagnosis or suspicion of a clinically unstable systemic medical disorder, or a physical illness currently causing severe physical and/or mental distress (e.g., an active flare of inflammatory bowel disease).
  • Pregnancy.
  • Current participation in another specific intervention focused on diet or exercise.
  • Diagnosis of severe psychiatric disorders, such as bipolar disorder type I or II, or a personality disorder as the primary clinical diagnosis.
  • Current substance use disorder.
  • Medical diagnosis that could explain or mask potential psychopathology, such as hormonal alterations (e.g., uncontrolled thyroid dysfunction).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universidad of Zaragoza

Zaragoza, Zaragoza, 50009, Spain

Location

MeSH Terms

Conditions

Anxiety DisordersDepression

Condition Hierarchy (Ancestors)

Mental DisordersBehavioral SymptomsBehavior

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

January 13, 2026

First Posted

February 9, 2026

Study Start

January 16, 2026

Primary Completion

February 28, 2026

Study Completion (Estimated)

September 30, 2026

Last Updated

February 9, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations